France
Omini, founded in 2019 and headquartered in France, is revolutionizing chronic disease management through its groundbreaking technology. The biotechnology company is developing the first point-of-care blood biomarker monitoring platform, a step-change in healthcare solutions aimed at chronic disease patients. Its tagline, "Personalized multiplex blood testing platform to monitor chronic diseases," underscores its mission to deliver personalized healthcare through its unique multiplex electrochemical biosensor technology.
The platform enables real-time monitoring and adjustment of therapies, potentially preventing acute crises in patients. The device, comparable to a glucometer, is designed for affordability and portability, capable of measuring multiple biomarkers from a simple capillary blood sample, usable at home or in outpatient settings. Currently, Omini is focusing on heart failure, often referred to as ‘the silent killer.’
The company recently attracted Pre Seed Round funding on 12 November 2024, supported by MEDKAP Investors. Positioned at the intersection of biotechnology and healthcare, Omini presents a compelling opportunity for investors seeking innovation in chronic disease management.
